Lifecore Biomedical, INC \de\ Form 4 insider transactions

LifeCore Biomedical's CEO, Paul Josephs, acquired 38,461 shares and disposed of 11,769 shares to cover tax obligations on December 6, 2024.

LifeCore Biomedical's Chief Financial Officer, Ryan Lake, reported the acquisition and disposal of company stock on December 6, 2024, including shares withheld for tax obligations.

Ryan David Lake, CFO of Lifecore Biomedical, reports the vesting of performance-based restricted stock units and subsequent transactions involving the company's common stock.

Wynnefield Partners Small Cap Value LP I reports acquiring additional shares of LifeCore Biomedical, Inc., increasing its beneficial ownership.

Legion Partners and related entities acquired additional shares of Lifecore Biomedical at $4.10 per share, increasing their beneficial ownership.

Humberto Calheiros Antunes, a director of Lifecore Biomedical, acquired 24,554 shares of common stock and amended a previous filing to include 3,000 inadvertently omitted shares.

Ryan David Lake, CFO of Lifecore Biomedical, acquired 262,500 shares of common stock and 750,000 performance-based restricted stock units on September 3, 2024.

Director Paul Harold Johnson acquired 24,554 shares of Lifecore Biomedical, Inc. common stock on August 19, 2024.

Director Humberto Calheiros Antunes acquired 24,554 shares of Lifecore Biomedical, Inc. common stock through restricted stock units.

Director Jason Aryeh acquired 24,554 shares of Lifecore Biomedical through restricted stock units that vest in 2025.

Director Matthew E. Korenberg reports acquisition of 24,554 restricted stock units in Lifecore Biomedical, Inc.

Director Craig A. Barbarosh acquired 30,000 shares of Lifecore Biomedical, Inc. common stock through restricted stock units.

Director Nathaniel Calloway acquired 30,000 shares of Lifecore Biomedical common stock on July 8, 2024, increasing his total holdings to 58,069 shares.

Raymond H. Diradoorian, a director of Lifecore Biomedical, acquired 30,000 shares of common stock on July 8, 2024.

Director Jeffrey Edwards acquired 30,000 shares of Lifecore Biomedical, Inc. common stock on July 8, 2024.

Director Houde Lovas Katrina reports acquisition of 30,000 shares of Lifecore Biomedical, Inc.

Director Nelson Obus reports acquiring 30,000 shares of Lifecore Biomedical common stock on July 8, 2024, increasing his direct holdings to 118,687 shares.

Director Joshua Schechter reports acquiring 30,000 shares of Lifecore Biomedical common stock through restricted stock units.

Christopher S. Kiper, along with Legion Partners and related entities, filed a Form 4 detailing changes in beneficial ownership of LifeCore Biomedical, Inc. securities due to the grant of restricted stock units.

Paul Josephs, CEO of Lifecore Biomedical, reports the acquisition of performance-based restricted stock units and the disposition of common stock to cover tax obligations.